Melbourne-based pharmaceutical company Pharmachal Health Group is hailing COVID-19 drug
TRIAZAVIRIN™ – otherwise known as TZV – as a “gamechanger”, with the drug dramatically cutting
rates of hospitalisation and death.
Pharmachal Health Group is pursuing Therapeutic Goods Administration approval to sell the drug as
an antiviral treatment for flu and Covid-19 in Australia under the Special Access Scheme, having
recently secured distribution and development rights for Australia, the Middle East, and several
south-east Asian countries.
Read Full Release:
PHG Media Release 19 Nov 2021 TZV
.pdf
Download PDF • 481KB
